Premier Path Wealth Partners’s Edwards Lifesciences EW Stock Holding History

Premier Path Wealth Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$291K	Sell	3,368 -416	-11%	-$37K	0.03%	328
2026 Q2	$342K	Sell	3,784 -96	-2%	-$8.04K	0.04%	335
2026 Q1	$311K	Buy	3,880 +162	+4%	+$13.4K	0.04%	341
2025 Q4	$317K	Sell	3,718 -476	-11%	-$39.1K	0.04%	316
2025 Q3	$326K	Sell	4,194 -16	-0.4%	-$1.25K	0.04%	316
2025 Q2	$329K	Buy	4,210 +395	+10%	+$29.5K	0.05%	312
2025 Q1	$277K	Buy	3,815 +8	+0.2%	+$573	0.04%	315
2024 Q4	$282K	Sell	3,807 -467	-11%	-$32.7K	0.04%	313
2024 Q3	$282K	Sell	4,274 -1,256	-23%	-$91.3K	0.04%	308
2024 Q2	$511K	Buy	5,530 +726	+15%	+$64.3K	0.09%	220
2024 Q1	$459K	Buy	4,804 +1	+0%	+$84	0.09%	221
2023 Q4	$366K	Buy	+4,803	New	+$334K	0.08%	225

Other funds holding EW

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One North America New York $2.13B AUM 8.8% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

ABN AMRO Investment Solutions Paris Cedex 008 $13.2B AUM 30.55% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Premier Path Wealth Partners's EW Position: Q3 2026 in Review

Premier Path Wealth Partners reduced its Edwards Lifesciences (EW) stake by 11% in Q3 2026, selling an estimated $37K and leaving 3,368 shares worth $291K. The position accounts for 0.03% of the portfolio, ranked #328.

Premier Path Wealth Partners first reported a position in EW in Q4 2023 and has held it in 12 quarters since. The position peaked at $511K in Q2 2024. 326 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Premier Path Wealth Partners held 3,368 shares of Edwards Lifesciences worth $291K as of Q3 2026.
Premier Path Wealth Partners sold 416 Edwards Lifesciences shares in Q3 2026, an estimated $37K.
Edwards Lifesciences made up 0.03% of Premier Path Wealth Partners's portfolio in Q3 2026, its #328 holding.
Premier Path Wealth Partners first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 12 quarters since.
Premier Path Wealth Partners's Edwards Lifesciences position peaked at $511K in Q2 2024.
326 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Premier Path Wealth Partners's 13F filing for Q3 2026, filed 16 Oct 2026.